FOSTER CITY, Calif. & ANN ARBOR, Mich.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) and EVOQ Therapeutics, Inc. (EVOQ) today announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ’s NanoDisc technology is designed to enable lymph targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases. Under the agreement, Gilead and EVOQ will collaborate on preclinical development. Gilead has the option to exclusively license rights to EVOQ’s NanoDisc technology to pursue product candidates for RA and lupus indications and will be responsible for clinical development and commercialization. See press release here.
Recent Posts
- Live cell screening to identify RNA-binding small molecule inhibitors of the pre-let-7–Lin28 RNA– protein interaction
- Structure–Activity Relationships of Natural and Semisynthetic Plecomacrolides Suggest Distinct Pathways for HIV-1 Immune Evasion and Vacuolar ATPase-Dependent Lysosomal Acidification
- AI is a Viable Alternative to High Throughput Screening
- New Assay for Discovery of Novel RNA Targeting Antibacterials
- Accelerating Drug Discovery in Michigan